Amicus Therapeutics, Inc. (FOLD)
Largest Insider Buys in Sector
FOLD Stock Price History Chart
FOLD Stock Performance
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate …
Insider Activity of Amicus Therapeutics, Inc.
Over the last 12 months, insiders at Amicus Therapeutics, Inc. have bought $0 and sold $7.22M worth of Amicus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Amicus Therapeutics, Inc. have bought $359,521 and sold $13.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,500 shares for transaction amount of $15,735 was made by WHITMAN BURKE W (director) on 2021‑11‑01.
List of Insider Buy and Sell Transactions, Amicus Therapeutics, Inc.
| 2024-11-06 | Sale | President and CEO | 7,901 0.003% | $12.50 | $98,800 | -5.78% | ||
| 2024-11-01 | Sale | President and CEO | 7,500 0.0025% | $11.46 | $85,960 | -5.54% | ||
| 2024-10-01 | Sale | President and CEO | 7,500 0.0025% | $10.60 | $79,493 | -0.61% | ||
| 2024-09-03 | Sale | President and CEO | 7,500 0.0025% | $11.71 | $87,798 | -5.46% | ||
| 2024-08-01 | Sale | President and CEO | 7,500 0.0026% | $10.34 | $77,519 | +10.10% | ||
| 2024-07-05 | Sale | President and CEO | 6,100 0.0021% | $10.00 | $61,029 | 0.00% | ||
| 2024-07-01 | Sale | President and CEO | 1,400 0.0005% | $10.00 | $14,003 | 0.00% | ||
| 2024-06-03 | Sale | President and CEO | 7,500 0.0025% | $10.00 | $75,000 | +5.96% | ||
| 2024-05-01 | Sale | President and CEO | 7,500 0.0024% | $10.07 | $75,524 | +0.77% | ||
| 2024-04-01 | Sale | President and CEO | 7,500 0.0025% | $11.67 | $87,496 | -10.13% | ||
| 2024-03-05 | Sale | director | 7,500 0.0025% | $13.40 | $100,500 | -20.16% | ||
| 2024-03-04 | Sale | director | 7,500 0.0025% | $13.29 | $99,675 | -20.84% | ||
| 2024-03-01 | Sale | President and CEO | 15,833 0.0053% | $13.14 | $208,017 | -19.79% | ||
| 2024-03-01 | Sale | Executive Chairman | 29,181 0.01% | $13.35 | $389,543 | -19.79% | ||
| 2024-02-15 | Sale | President and CEO | 4,167 0.0015% | $14.00 | $58,338 | -23.57% | ||
| 2024-02-15 | Sale | Executive Chairman | 31,614 0.0113% | $13.81 | $436,551 | -23.57% | ||
| 2024-02-15 | Sale | Chief People Officer | 4,427 0.0016% | $14.00 | $61,978 | -23.57% | ||
| 2024-02-07 | Sale | Chief Legal Officer | 29,600 0.0104% | $13.00 | $384,818 | -16.62% | ||
| 2024-02-06 | Sale | Chief Legal Officer | 400 0.0001% | $13.00 | $5,200 | -16.22% | ||
| 2024-02-01 | Sale | President and CEO | 15,833 0.0054% | $12.56 | $198,858 | -13.34% |
Insider Historical Profitability
| Campbell Bradley L | President and CEO | 886654 0.2967% | $9.57 | 3 | 79 | +51.18% |
| Crowley John F | Executive Chairman | 573478 0.1919% | $9.57 | 5 | 162 | <0.0001% |
| Rosenberg Ellen | Chief Legal Officer | 367654 0.123% | $9.57 | 1 | 12 | <0.0001% |
| Castelli Jeff | Chief Development Officer | 340661 0.114% | $9.57 | 3 | 12 | |
| MCGLYNN MARGARET G | director | 59289 0.0198% | $9.57 | 1 | 8 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $332.25M | 9.52 | 28.2M | -1.01% | -$3.39M | 0.01 | |
| Perceptive Advisors | $330.52M | 9.47 | 28.06M | 0% | +$0 | 0.21 | |
| Avoro Capital Advisors Llc | $322.77M | 9.25 | 27.4M | 0% | +$0 | 3.87 | |
| BlackRock | $269.17M | 7.71 | 22.85M | -0.6% | -$1.63M | 0.01 | |
| Wellington Management Company | $221.51M | 6.35 | 18.8M | +23.79% | +$42.57M | 0.04 |